A phase II study of ACR-368 and low dose gemcitabine combination therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Category Primary study
ConferenceASCO MEETING ABSTRACTS
Year 2025
This article has no abstract
Epistemonikos ID: b7e077f685872e97ed4d64d4b5bd3a01759ad629
First added on: May 16, 2026